v3.26.1
10-K Consolidated Statements of Temporary Equity and Shareholders' Equity - USD ($)
$ in Thousands
Total
Reclassifications
Common shares
SVS
Common shares
MVS
 [4]
Additional paid-in capital
Additional paid-in capital
Reclassifications
Treasury
shares
Treasury
shares
Reclassifications
Accumulated other comprehensive loss
Accumulated
deficit
Redeemable non-controlling interest, beginning balance at Dec. 31, 2022 $ 121,113                  
Changes in redeemable non-controlling interest contingency                    
Excess carrying value of redeemed non-controlling interest over consideration paid in SVS [1],[2] 0                  
Contribution from non-controlling interest 4,166                  
Foreign currency translation gain (loss) 4,511                  
Excess redemption value above carrying value [1] 0                  
Net income (loss) (9,140)                  
Redeemable non-controlling interest, ending balance at Dec. 31, 2023 120,650                  
Common stock, beginning balance (in shares) at Dec. 31, 2022     207,840,042 [3] 31,323,568            
Balance, beginning of period at Dec. 31, 2022 1,279,705 $ 0     $ 2,163,061 $ (5,208) $ (5,208) $ 5,208 $ (18,594) $ (859,554)
Changes in stockholders equity                    
Issuance of shares — acquisitions (in shares) [3]     4,109,668              
Issuance of shares in connection with acquisitions 17,375       17,375          
Issuance of shares — public offering (in shares) [3]     900,000              
Issuance of shares - public offering 11,497       11,497          
SVS contributed to Curaleaf, Inc. (Reorganization) (in shares) [3],[5]     (84,772)              
SVS contributed to Curaleaf, Inc. (Reorganization) [3],[5] (1,050)           (1,050)      
Escrow shares returned and retired (in shares) [3]     (116,931)              
Escrow shares returned and retired (2,465)       (2,465)          
Foreign currency translation gain (loss) 6,719               6,719  
Exercise of stock options (in shares) [3]     70,590              
Exercise of stock options 48       48          
Issuance of SVS for settlement of RSUs (in shares) [3],[6]     533,768              
Share-based compensation 20,010       20,010          
Net comprehensive loss attributable to Curaleaf Holdings, Inc. (281,197) [7]                 (281,197)
Common stock, ending balance (in shares) at Dec. 31, 2023     213,252,365 [3] 31,323,568            
Balance, end of period at Dec. 31, 2023 1,050,642 $ (488)     2,204,318 $ (1,538) (1,050) $ 1,050 (11,875) (1,140,751)
Changes in redeemable non-controlling interest contingency                    
Excess carrying value of redeemed non-controlling interest over consideration paid in SVS [2] 0                  
Foreign currency translation gain (loss) (4,633)                  
Excess redemption value above carrying value 22,746                  
Net income (loss) (6,584)                  
Redeemable non-controlling interest, ending balance at Dec. 31, 2024 132,179                  
Changes in stockholders equity                    
Issuance of shares — acquisitions (in shares) [3]     4,266,930              
Issuance of shares in connection with acquisitions 32,117       32,117          
Escrow shares returned and retired (in shares) [3]     (56,719)              
Escrow shares returned and retired (535)       (535)          
Foreign currency translation gain (loss) (8,205)               (8,205)  
Exercise of stock options (in shares) [3]     25,130              
Exercise of stock options 156       156          
Issuance of SVS for settlement of RSUs (in shares) [3],[6]     1,076,186              
Issuance of SVS for settlement of PSUs (in shares) [3],[6]     132,179              
Excess redemption value above carrying value (22,746)       (22,746)          
Share-based compensation 25,696       25,696          
Net comprehensive loss attributable to Curaleaf Holdings, Inc. $ (215,423) [7]                 (215,423)
Common stock, ending balance (in shares) at Dec. 31, 2024 250,019,639   218,696,071 [3],[8] 31,323,568            
Balance, end of period at Dec. 31, 2024 $ 861,214       2,237,468   0   (20,080) (1,356,174)
Changes in redeemable non-controlling interest contingency                    
Foreign currency translation gain (loss) 2,756                  
Excess redemption value above carrying value 13,327                  
Net income (loss) 817                  
Redeemable non-controlling interest, ending balance at Mar. 31, 2025 149,079                  
Changes in stockholders equity                    
Extinguishment of convertible notes — issuance of SVS (in shares) [8]     1,427,532              
Extinguishment of convertible notes — issuance of SVS [8] 16,500       16,500          
Foreign currency translation gain (loss) 6,063               6,063  
Exercise of stock options (in shares) [8]     33,333              
Exercise of stock options 10       10          
Issuance of SVS for settlement of RSUs (in shares) [8],[9]     556,208              
Issuance of SVS for settlement of PSUs (in shares) [8],[9]     119,983              
Excess redemption value above carrying value (13,327)       (13,327)          
Share-based compensation 4,624       4,624          
Net comprehensive loss attributable to Curaleaf Holdings, Inc. (61,063)                 (61,063)
Common stock, ending balance (in shares) at Mar. 31, 2025     220,833,127 [8] 31,323,568            
Balance, end of period at Mar. 31, 2025 814,021       2,245,275       (14,017) (1,417,237)
Redeemable non-controlling interest, beginning balance at Dec. 31, 2024 132,179                  
Changes in redeemable non-controlling interest contingency                    
Issuance of SVS to settle NCI [3] (5,418)                  
Excess carrying value of redeemed non-controlling interest over consideration paid in SVS [2],[3] (96,696)                  
Foreign currency translation gain (loss) 8,655                  
Excess redemption value above carrying value 42,294                  
Net income (loss) 2,917                  
Redeemable non-controlling interest, ending balance at Dec. 31, 2025 $ 83,931                  
Common stock, beginning balance (in shares) at Dec. 31, 2024 250,019,639   218,696,071 [3],[8] 31,323,568            
Balance, beginning of period at Dec. 31, 2024 $ 861,214       2,237,468   0   (20,080) (1,356,174)
Changes in stockholders equity                    
Extinguishment of convertible notes — issuance of SVS (in shares) [3]     1,427,532              
Extinguishment of convertible notes — issuance of SVS [3] 16,500       16,500          
Issuance of SVS to settle non-controlling interest (in shares) [3]     2,270,284              
Issuance of SVS to settle non-controlling interest [3] 5,418       5,418          
Excess carrying value of redeemed non-controlling interest over consideration in SVS [3] 96,696       96,696          
Acquisition related contingent equity consideration (in shares) [3]     207,055              
Acquisition related contingent equity consideration 497       497          
Acquisition related deferred equity consideration (in shares) [3]     1,920,907              
Acquisition related deferred equity consideration 77       77          
Foreign currency translation gain (loss) 18,272               18,272  
Exercise of stock options (in shares) [3]     621,424              
Exercise of stock options 256       256          
Issuance of SVS for settlement of liability (in shares) [3],[10]     32,017              
Issuance of SVS for settlement of liability [3],[10] 77       77          
Issuance of SVS for settlement of RSUs (in shares) [3],[6]     872,741              
Issuance of SVS for settlement of PSUs (in shares) [3],[6]     119,983              
Excess redemption value above carrying value (42,294)       (42,294)          
Share-based compensation 30,707       30,707          
Net comprehensive loss attributable to Curaleaf Holdings, Inc. $ (231,070)                 (231,070)
Common stock, ending balance (in shares) at Dec. 31, 2025 257,491,582   226,168,014 [3],[8] 31,323,568            
Balance, end of period at Dec. 31, 2025 $ 756,350       2,345,402   $ 0   (1,808) (1,587,244)
Changes in redeemable non-controlling interest contingency                    
Foreign currency translation gain (loss) 3,701                  
Excess redemption value above carrying value 381                  
Net income (loss) (16)                  
Redeemable non-controlling interest, ending balance at Mar. 31, 2026 87,997                  
Changes in stockholders equity                    
Foreign currency translation gain (loss) $ (8,354)               (8,354)  
Exercise of stock options (in shares) 996,576   996,576 [8]              
Exercise of stock options $ 478       478          
Issuance of SVS for settlement of RSUs (in shares) [8],[9]     1,995,496              
Issuance of SVS for settlement of PSUs (in shares) [8],[9]     928,214              
Excess redemption value above carrying value (381)       (381)          
Share-based compensation 9,664       9,664          
Net comprehensive loss attributable to Curaleaf Holdings, Inc. $ 69,799                 69,799
Common stock, ending balance (in shares) at Mar. 31, 2026 260,491,464   229,167,896 [8] 31,323,568            
Balance, end of period at Mar. 31, 2026 $ 821,112       $ 2,348,719       $ (10,162) $ (1,517,445)
[1]
(1) Amounts reported in the Company’s Annual Financial Statements for the years ended December 31, 2023 have been recast to reflect reclassification of Missouri and Hemp-derived THC operations as discontinued operations.
[2]
*as defined herein
[3]
*as defined in Note 1 — Operations of the Company
[4]
***as defined in Note 2 — Basis of presentation
[5]
(2) See the section titled "2023 change in ownership" in Note 2 - Basis of presentation for additional details.
[6]
**as defined in Note 3 — Significant accounting policies
[7]
(1) Amounts reported in the Company’s Annual Financial Statements for the years ended December 31, 2023 have been recast to reflect reclassification of Missouri and Hemp-derived THC operations as discontinued operations.
[8]
*as defined in Note 1 — Operations of the Company
[9]
**as defined in Note 3 — Significant accounting policies
[10]
(1) The Company issued shares to settle a liability stemming from then-outstanding supply obligations.